412 related articles for article (PubMed ID: 26452397)
1. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
[TBL] [Abstract][Full Text] [Related]
5. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
Levin MJ; Smith JG; Kaufhold RM; Barber D; Hayward AR; Chan CY; Chan IS; Li DJ; Wang W; Keller PM; Shaw A; Silber JL; Schlienger K; Chalikonda I; Vessey SJ; Caulfield MJ
J Infect Dis; 2003 Nov; 188(9):1336-44. PubMed ID: 14593591
[TBL] [Abstract][Full Text] [Related]
6. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
Weinberg A; Zhang JH; Oxman MN; Johnson GR; Hayward AR; Caulfield MJ; Irwin MR; Clair J; Smith JG; Stanley H; Marchese RD; Harbecke R; Williams HM; Chan IS; Arbeit RD; Gershon AA; Schödel F; Morrison VA; Kauffman CA; Straus SE; Schmader KE; Davis LE; Levin MJ;
J Infect Dis; 2009 Oct; 200(7):1068-77. PubMed ID: 19712037
[TBL] [Abstract][Full Text] [Related]
7. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.
Levin MJ; Oxman MN; Zhang JH; Johnson GR; Stanley H; Hayward AR; Caulfield MJ; Irwin MR; Smith JG; Clair J; Chan IS; Williams H; Harbecke R; Marchese R; Straus SE; Gershon A; Weinberg A;
J Infect Dis; 2008 Mar; 197(6):825-35. PubMed ID: 18419349
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
[TBL] [Abstract][Full Text] [Related]
10. Varicella-zoster virus-specific cell-mediated immunity in subjects with herpes zoster.
Otani N; Yamanishi K; Sakaguchi Y; Imai Y; Shima M; Okuno T
J Immunol Methods; 2012 Mar; 377(1-2):53-5. PubMed ID: 22261191
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
[TBL] [Abstract][Full Text] [Related]
12. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
J Virol; 2021 May; 95(12):. PubMed ID: 33762414
[TBL] [Abstract][Full Text] [Related]
13. Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.
Berger R; Luescher D; Just M
Postgrad Med J; 1985; 61 Suppl 4():143-5. PubMed ID: 3014472
[TBL] [Abstract][Full Text] [Related]
14. Comparative Immune Responses to Licensed Herpes Zoster Vaccines.
Weinberg A; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Levin MJ
J Infect Dis; 2018 Sep; 218(suppl_2):S81-S87. PubMed ID: 30247596
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
Macaladad N; Marcano T; Guzman M; Moya J; Jurado F; Thompson M; Meechan C; Li D; Schlienger K; Chan I; Sadoff J; Schödel F; Silber JL
Vaccine; 2007 Mar; 25(11):2139-44. PubMed ID: 17250932
[TBL] [Abstract][Full Text] [Related]
16. Th1 memory differentiates recombinant from live herpes zoster vaccines.
Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
[TBL] [Abstract][Full Text] [Related]
18. Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine.
Weinberg A; Popmihajlov Z; Schmader KE; Johnson MJ; Caldas Y; Salazar AT; Canniff J; McCarson BJ; Martin J; Pang L; Levin MJ
J Infect Dis; 2019 Jan; 219(2):335-338. PubMed ID: 30165651
[TBL] [Abstract][Full Text] [Related]
19. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.
Sullivan NL; Reuter-Monslow MA; Sei J; Durr E; Davis CW; Chang C; McCausland M; Wieland A; Krah D; Rouphael N; Mehta AK; Mulligan MJ; Pulendran B; Ahmed R; Vora KA
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743372
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
